Peter Rossing, ADA 2022: The combined use of finerenone and GLP-1RA for chronic kidney disease and type 2 diabetes, the FIDELITY analysis

The combined use of finerenone and glucagon-like peptide-1 receptor agonist (GLP-1RA) for chronic kidney disease (CKD) and type 2 diabetes (T2D) was studied in the FIDELITY analysis, and is discussed by Professor Peter Rossing (Steno Diabetes Center, Copenhagen, Denmark). The purpose of the FIDELITY analysis, an extended analysis of the FIDELIO-DKD and FIGARO-DKD studies, was to examine how two guideline recommended treatments for CKD and T2D interact.  

The abstract entitled ‘Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.

Questions: 

1. Could you give us a brief overview of the FIDELIO-DKD and FIGARO-DKD studies and their findings in terms of the impact of finerenone on cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes? (0:27)
2. What was the rationale for the current analyses of data from the two studies? (2:14)
3. What were the findings of the analysis in terms of the effect of GLP-1RA use at baseline? (4:30)
4. What do these findings tell us about the mechanism of reduction in albuminuria? (5:45)
5. What questions remain unanswered and what future studies are planned? (8:00)

Disclosures: Peter Rossing is a consultant for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, MSD, Novo Nordisk and Sanofi. Peter Rossing has received grant/research support from: AstraZeneca and Novo Nordisk.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ADA 2022.